Prosecution Insights
Last updated: November 21, 2026
Application No. 18/212,168

BIOHAZARD ANALYZER

Final Rejection §103§112
Filed
Jun 20, 2023
Priority
Feb 28, 2019 — provisional 62/811,617 +1 more
Examiner
LUSI, ELLIS FOLLETT
Art Unit
1677
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
University of Utah Research Foundation
OA Round
2 (Final)
64%
Grant Probability
Moderate
3-4
OA Rounds
6m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
49 granted / 76 resolved
+4.5% vs TC avg
Strong +54% interview lift
Without
With
+54.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
35 currently pending
Career history
113
Total Applications
across all art units

Statute-Specific Performance

§101
7.1%
-32.9% vs TC avg
§103
33.9%
-6.1% vs TC avg
§102
14.8%
-25.2% vs TC avg
§112
32.2%
-7.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 76 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-3 and 9-14 are pending in the application and are the subject of this office action. Claim Interpretation The following is a quotation of 35 U.S.C. 112(f): (f) Element in Claim for a Combination. – An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The following is a quotation of pre-AIA 35 U.S.C. 112, sixth paragraph: An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. The broadest reasonable interpretation of a claim element (also commonly referred to as a claim limitation) is limited by the description in the specification when 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is invoked. As explained in MPEP § 2181, subsection I, claim limitations that meet the following three-prong test will be interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph: (A) the claim limitation uses the term “means” or “step” or a term used as a substitute for “means” that is a generic placeholder (also called a nonce term or a non-structural term having no specific structural meaning) for performing the claimed function; (B) the term “means” or “step” or the generic placeholder is modified by functional language, typically, but not always linked by the transition word “for” (e.g., “means for”) or another linking word or phrase, such as “configured to” or “so that”; and (C) the term “means” or “step” or the generic placeholder is not modified by sufficient structure, material, or acts for performing the claimed function. Use of the word “means” (or “step”) in a claim with functional language creates a rebuttable presumption that the claim limitation is to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites sufficient structure, material, or acts to entirely perform the recited function. Absence of the word “means” (or “step”) in a claim creates a rebuttable presumption that the claim limitation is not to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is not interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites function without reciting sufficient structure, material or acts to entirely perform the recited function. Claim limitations in this application that use the word “means” (or “step”) are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Conversely, claim limitations in this application that do not use the word “means” (or “step”) are not being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. This application includes one or more claim limitations that do not use the word “means,” but are nonetheless being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, because the claim limitation(s) uses a generic placeholder that is coupled with functional language without reciting sufficient structure to perform the recited function and the generic placeholder is not preceded by a structural modifier. Such claim limitation(s) is/are: In claim 1: “the first and second antibodies are configured to form a complex comprising a pathogen, the nonmagnetic metal, and the magnetic object” This limitation is interpreted under 112(f) because it recites a particular function associated with a particular element, wherein the structural description of the associated element is insufficient to support the recited function. That is, a generic first and second antibody are not necessarily capable of forming a complex comprising a pathogen, the nonmagnetic metal, and the magnetic object. As such, this limitation is interpreted in view of the associated structure provided in the instant specification. The instant specification indicates that formation of such a complex is facilitated by a first antibody which is capable of specifically binding to the pathogen, and a second antibody which is either capable of specifically binding to the pathogen or is capable of specifically binding to the Fc region of the first antibody (see instant specification Par. 9-10 and instant claims 2-3). In claim 1: “the sample mixing chamber is configured to sequentially receive the first antibody coupled to the nonmagnetic metal and the second antibody coupled to the magnetic object according to a relative particle size of the first antibody coupled to the nonmagnetic metal and the second antibody coupled to the magnetic object” This limitation is interpreted under 112(f) because it recites a particular function associated with a particular element, wherein the structural description of the associated element is insufficient to support the recited function. Further claim interpretation is discussed in the 112(b) section below. In claim 1: “the complex configured to adhere to the electrode, wherein the nonmagnetic metal adheres to a surface of the electrode” This limitation is interpreted under 112(f) because it recites a particular function associated with a particular element, wherein the structural description of the associated element is insufficient to support the recited function. That is, a generic nonmagnetic metal of the complex is not necessarily capable of adhering to a generic electrode, such that additional structure is required to facilitate this function. Further claim interpretation is discussed in the 112(b) section below. Because this/these claim limitation(s) is/are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, it/they is/are being interpreted to cover the corresponding structure described in the specification as performing the claimed function, and equivalents thereof. If applicant does not intend to have this/these limitation(s) interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, applicant may: (1) amend the claim limitation(s) to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph (e.g., by reciting sufficient structure to perform the claimed function); or (2) present a sufficient showing that the claim limitation(s) recite(s) sufficient structure to perform the claimed function so as to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. Claim Rejections - 35 USC § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-3 and 9-14 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Amended claim 1 recites: “the sample mixing chamber is configured to sequentially receive the first antibody coupled to the nonmagnetic metal and the second antibody coupled to the magnetic object according to a relative particle size of the first antibody coupled to the nonmagnetic metal and the second antibody coupled to the magnetic object” wherein the language “configured to” implies some specific structural arrangement or modification of the sample mixing chamber which facilitates the recited function of sequentially receiving different components based on relative particle size. However, the language of this limitation does not appear in the specification, and the disclosure does not support this limitation. The specification at Par. 57-58 instead describes introducing different components in sequence as a matter of intended use (i.e. sequential introduction of component based on relative particle size is a step in the method of using the system, but is not a structural feature of the system or the sample mixing chamber itself). As such, the disclosure does not support the recitation that the sample mixing chamber is specifically “configured” for this particular function. This is a new matter rejection. Dependent claims 2-3 and 9-14 are rejected because they depend from a rejected claim and fail to remedy its deficiencies. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-3 and 9-14 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim limitation “the sample mixing chamber is configured to sequentially receive the first antibody coupled to the nonmagnetic metal and the second antibody coupled to the magnetic object according to a relative particle size of the first antibody coupled to the nonmagnetic metal and the second antibody coupled to the magnetic object” in claim 1 invokes 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. However, the written description fails to disclose the corresponding structure, material, or acts for performing the entire claimed function and to clearly link the structure, material, or acts to the function. The language “configured to” implies some specific structural arrangement or modification of the sample mixing chamber which facilitates the recited function of sequentially receiving different components based on relative particle size. However, the language of this limitation does not appear in the specification, and the disclosure does not describe any particular physical structure or modification of the sample mixing chamber which is responsible for facilitating this recited function. The specification at Par. 57-58 instead describes introducing different components in sequence as a matter of intended use (i.e. sequential introduction of component based on relative particle size is a step in the method of using the system, but is not described as a structural feature of the system or the sample mixing chamber itself). Therefore, the structure required to facilitate the recited function is unclear, and moreover, whether or not the recitation actually requires any particular structure or modification beyond a generic sample mixing chamber is unclear. Therefore, the claim is indefinite and is rejected under 35 U.S.C. 112(b) or pre-AIA 35 U.S.C. 112, second paragraph. Claim limitation “the complex configured to adhere to the electrode, wherein the nonmagnetic metal adheres to a surface of the electrode” in claim 1 invokes 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. However, the written description fails to disclose the corresponding structure, material, or acts for performing the entire claimed function and to clearly link the structure, material, or acts to the function. As noted in the claim interpretation section above, a nonmagnetic metal as described in the instant claim is not inherently capable of adhering to a surface of the electrode as described in the instant claim. That is, the claim provides no structural description or detail that specifically denotes how the complex/nonmagnetic metal is “configured to” adhere to a surface of the electrode, such that the structural limitations applied by this recitation are unclear. The specification provides some discussion of an embodiment wherein the nonmagnetic metal adheres to the surface of an electrode (Par. 46) but it is not clear from the description what particular structural features of the complex, nonmagnetic metal, and/or the electrode facilitate this adherence. In light of this, and the disclosure as a whole, the particular structural features of the system that are responsible for facilitating the recited adherence with the surface of the electrode are unclear, and thus the metes and bounds of the limitation are unclear. Therefore, the claim is indefinite and is rejected under 35 U.S.C. 112(b) or pre-AIA 35 U.S.C. 112, second paragraph. Applicant may: (a) Amend the claim so that the claim limitation will no longer be interpreted as a limitation under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph; (b) Amend the written description of the specification such that it expressly recites what structure, material, or acts perform the entire claimed function, without introducing any new matter (35 U.S.C. 132(a)); or (c) Amend the written description of the specification such that it clearly links the structure, material, or acts disclosed therein to the function recited in the claim, without introducing any new matter (35 U.S.C. 132(a)). If applicant is of the opinion that the written description of the specification already implicitly or inherently discloses the corresponding structure, material, or acts and clearly links them to the function so that one of ordinary skill in the art would recognize what structure, material, or acts perform the claimed function, applicant should clarify the record by either: (a) Amending the written description of the specification such that it expressly recites the corresponding structure, material, or acts for performing the claimed function and clearly links or associates the structure, material, or acts to the claimed function, without introducing any new matter (35 U.S.C. 132(a)); or (b) Stating on the record what the corresponding structure, material, or acts, which are implicitly or inherently set forth in the written description of the specification, perform the claimed function. For more information, see 37 CFR 1.75(d) and MPEP §§ 608.01(o) and 2181. Dependent claims 2-3 and 9-14 are rejected because they depend from a rejected claim and fail to remedy its deficiencies. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-2, 9-10, 12-14 are rejected under 35 U.S.C. 103 as being unpatentable over Lowe et al (US 2011/0053289 Al; IDS entered) in view of Mattingly (US 2009/0246800 Al; IDS entered). Regarding claims 1-2, 9-10, 13-14 Lowe teaches a system for detecting an analyte in a sample comprising: A first antibody coupled to a nonmagnetic metal, wherein the nonmagnetic metal comprises gold, silver, aluminum, copper, lead, tin, titanium, zinc, brass, bronze, an alloy thereof, or a combination thereof (Par. 24-25: the second reagent may comprise a binding agent capable of binding to analyte in the first liquid. The binding agent of the second reagent may be capable of binding to a different epitope of the analyte than the binding agent of the first reagent. The binding agent of the second reagent may be an antibody. The second reagent may be conjugated to a second particle (e.g. a non-magnetic particle such as a sol particle (e.g. a gold sol)). The second particle may comprise at least one label; Par. 83,458,559,645); A second antibody coupled to a magnetic object (Par. 23: the first reagent may comprise magnetically susceptible particles comprising a binding agent adapted to bind to an analyte in the first liquid. The first binding agent may be an antibody that binds specifically to the analyte; Par. 82); First and second antibodies configured to form a complex comprising a pathogen, the nonmagnetic metal, and the magnetic object (Par. 80: the method may include forming complexes of magnetically susceptible particle, analyte and second binding agent; Par. 464, 23-25); A sample mixing chamber (Par. 75: introducing a liquid sample to a first portion of a channel of a microfluidic device and contacting the liquid sample with the magnetic particles); Regarding the limitation “wherein the sample mixing chamber is configured to sequentially receive…and the second antibody coupled to the magnetic object”, this is noted as a recitation of intended use, as described above, because there is no indication in either the claims or the specification of any particular structural feature or modification of the sample mixing chamber that specifically facilitates this function. Instead, the specification at Par. 57-58 indicates that sequential introduction of different components is a step in a process of using the claimed system. A recitation of intended use does not distinguish over the prior art in a claim to a product or system because a product is defined by what it is and not by what it does. As long as the prior art teaches all structural requirements of the product claim, it is understood to meet the instant claim, regardless of whether it explicitly teaches the same intended use. As such, because Lowe is understood to teach all structural requirements of the instant claim, as described herein, it is understood to meet this limitation of the instant claim. A magnet positioned to be adjacent to the sample mixing chamber (Par. 75; Par. 98: positioning the magnetic particles can be performed using a magnet located external to the channel); An electrode in selective communication with the sample mixing chamber (Par. 54: any sensor of the device may include at least one electrode; Par. 14: the device comprises an inlet in fluid connection with a first portion of a channel, the inlet configured to receive a liquid; a second portion of the channel connected to the first portion at a junction and containing flowable media between the junction and a detection zone is a second channel portion; Par. 18, 33, 423, 426-437, 479, 503); the complex configured to adhere to the electrode, wherein the nonmagnetic metal adheres to a surface of the electrode (as best interpreted in view of the 112(b) issues discussed above) (Par. 108-109: the method may comprise magnetically moving the magnetic particle adjacent to or upon a sensor located in or juxtaposed to the second channel portion of the device. The particle may be magnetically retained adjacent to or upon the sensor for an amount of time sufficient for the sensor to detect a characteristic of the second liquid. The method may include magnetically positioning the magnetic particles adjacent to or upon the one or more electrode for the detection of the analyte). That is, the nonmagnetic metal is understood to be able to adhere with the electrode in the invention of Lowe in that the nonmagnetic metal is configured to form a complex with the analyte and the magnetic particles (via specific binding of the first antibody to the analyte) such that the complex (comprising the nonmagnetic metal) may be magnetically positioned onto the electrode for detection of the analyte. A voltmeter in communication with the electrode, wherein adhesion of the nonmagnetic metal to the electrode changes a voltage measured by the voltmeter (Par. 336,447,471, 598). Lowe teaches that the analyte is not particularly limited, but does not explicitly teach that the analyte is a pathogen (Par. 434: the analyte may be any analyte, and more particularly, any analyte to which a binding agent, such as an antibody, may be raised). Lowe teaches that it is particularly desirable to detect analytes which facilitate diagnosis of a pathological condition (Par. 411, 438). Mattingly teaches a method of detecting a pathogen in a sample which comprises a sandwich format immunoassay comprising anti-pathogen antibodies (Abstract; Par. 105). Mattingly teaches that the analyte detected may be a pathogen, wherein detection of a pathogen may be useful in diagnosis or monitoring of disease (Par. 29, 62). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have modified the system of Lowe for the detection of a pathogen, as taught by Mattingly. One of ordinary skill in the art would be motivated to make this modification because Lowe teaches that the system may be used for the detection of any analyte and that analytes which are useful for the detection of pathological conditions are of particular interest, while Mattingly teaches that pathogens may be detected by antibodies in an immunoassay and may be used to diagnose and monitor disease/pathological conditions. One of ordinary skill in the art would have a reasonable expectation of success in making this modification because Lowe teaches that the analyte may be any analyte that can be specifically bound by an antibody, and Mattingly teaches that pathogen analytes may be specifically bound and detected by antibodies. Regarding claim 12, Lowe further teaches the system comprising a database configured to determine a concentration of the pathogen based on a presence of the nonmagnetic metal at the electrode (Par. 470-471, 597-604, 786-792, 838-844). Claim 3 is rejected under 35 U.S.C. 103 as being unpatentable over Lowe et al (US 2011/0053289 Al; IDS entered) in view of Mattingly (US 2009/0246800 Al; IDS entered) as applied to claim 1 above, and further in view of Thermo Fisher Scientific (Thermo Fisher Scientific Inc. Tech Tip #59: Choosing a secondary antibody: a guide to fragment specificity. 2007; previously cited). Regarding claim 3, Lowe differs from the instant claim in that it does not explicitly teach the system wherein the first antibody is specific for the pathogen and the second antibody is specific for the Fc region of the first antibody. Regarding claim 3, Thermo Fisher Scientific teaches that the use of labeled secondary antibodies which bind to the Fc region of a primary antibody-analyte complex is a well-known and common method of labeling and thereby detecting a primary antibody-analyte complex. Thermo Fisher Scientific teaches that the use of a secondary antibody that binds to a primary antibody can be advantageous (Pg. 1, Introduction, Sections A and C). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have modified the system of Lowe such that the first antibody is specific for the pathogen and the second antibody is specific for the Fc region of the first antibody. One would be motivated to make this modification because the use of a secondary antibody that binds specifically to the Fc region of an anti-analyte primary antibody is well-known in the art, as taught by Thermo Fisher Scientific and has a number of advantages. For example, the use of a secondary antibody that binds to the primary antibody mitigates potential steric hindrance between a first and second antibody that both bind to the same analyte molecule; a secondary antibody only needs to be specific for binding to the host species of the primary antibody (rather than specific to a particular epitope of the target analyte), and as such, these reagents are more generally available and easy to obtain, and can be used in a broader range of applications (i.e. the same Fe-binding secondary antibody can be used in the detection of a number of different analytes, as long as it is capable of binding to the chosen primary antibody, whereas an analyte-specific second antibody can only be used in the detection of one analyte); because they have a broader range of applications and are more generally available, secondary antibodies that bind to the Fc region of a primary antibody are generally commercially available and can be purchased in a pre-labeled state. One of ordinary skill in the art would have a reasonable expectation of success in making this modification because Lowe teaches that a target analyte can be detected by a complex comprising first and second antibodies, while Thermo Fisher Scientific teaches that first and second antibodies used in the detection of an analyte may comprise a primary antibody that binds to the target analyte and a secondary antibody that binds to the Fc region of the primary antibody, and that this is a well-known detection method in the art. Claim 11 is rejected under 35 U.S.C. 103 as being unpatentable over Lowe et al (US 2011/0053289 Al; IDS entered) in view of Mattingly (US 2009/0246800 Al; IDS entered) as applied to claim 1 above, and further in view of Xu et al ( (2012), Disposable Electrochemical Immunosensor by Using Carbon Sphere/Gold Nanoparticle Composites as Labels for Signal Amplification. Chem. Eur. J., 18: 4994-4998.). Regarding claim 11, Lowe in view of Mattingly differs from the instant claim in that it does not explicitly teach the system wherein the nonmagnetic metal is incorporated into a nonmagnetic carrier comprising a nonmetallic material. Xu discloses systems and methods for detecting an analyte in a sample via electrochemical immunosensing (Abstract). Xu discloses the use of carbon sphere/gold nanoparticle composites as labels for signal amplification, wherein the nonmagnetic metal (gold) is incorporated into a nonmagnetic carrier comprising a nonmetallic material (carbon sphere) and teaches that these labels are useful in improving the specificity and sensitivity of electrochemical immunosensing (Pg. 4995, Col. 1, Par. 1; Conclusion). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have modified the system of Lowe in view of Mattingly such that a gold label is incorporated into a nonmagnetic carrier comprising a nonmetallic material, as taught by Xu. One of ordinary skill in the art would be motivated to make this modification because Xu teaches that carbon sphere/gold nanoparticle composite labels can be used to increase specificity and sensitivity in electrochemical immunosensing. One of ordinary skill in the art would have a reasonable expectation of success in making this modification because both Lowe and Xu are directed to electrode immunoassays for the detection of an analyte in a sample, wherein the immunoassay system comprises a gold label conjugated to a specific binding agent. Response to Arguments Applicant’s arguments filed 29 September 2026 have been fully considered. Previous objections to the specification are withdrawn in view of the amendments to the specification. Regarding the applicability of 112(f), Applicant states that the phrasing “means for” has not been employed in claim 1 and Applicant does not intend to be limited to the provisions of 35 U.S.C. 112(f), however, 112(f) interpretation has been applied, as described above, for recitations which link a particular element to a particular function, wherein the structure provided in the claim is insufficient to support the recited function. Previous grounds of 112(b) rejection are withdrawn in view of the amendments to the claims. New grounds of 112(b) rejections which address the amended claims are presented above. Regarding the 103 rejection, Applicant argues that the cited prior art does not teach the amended limitation “wherein the sample mixing chamber is configured to sequentially receive the first antibody coupled to the nonmagnetic metal and the second antibody coupled to the magnetic object according to a relative particle size of the first antibody coupled to the nonmagnetic metal and the second antibody coupled to the magnetic object”; Applicant indicates that this amendment is supported by Par. 57-58 of the specification. This argument is not persuasive. As noted in the rejections above, Par. 57-58 appear to describe an intended method of using the claimed system wherein particular components are introduced to the sample mixing chamber sequentially, but the specification does not describe any particular structure or modification of the sample chamber that is responsible for facilitating this function. As such, the amended limitation appears to be a recitation of intended use which does not structurally limit the claimed system and which therefore does not distinguish the system over the prior art. Prior art which teaches all structural requirements of the claimed system is understood to meet the instant claim, regardless of whether it explicitly teaches the same intended use/method of using. As such, the cited prior art is understood to meet the amended claim. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ELLIS LUSI whose telephone number is (571)270-0694. The examiner can normally be reached M-Th 8am-6pm ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bao-Thuy Nguyen can be reached at (571) 272-0824. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ELLIS FOLLETT LUSI/Examiner, Art Unit 1677 /CHRISTOPHER L CHIN/Primary Examiner, Art Unit 1677
Read full office action

Prosecution Timeline

Jun 20, 2023
Application Filed
May 29, 2026
Non-Final Rejection mailed — §103, §112
Sep 29, 2026
Response Filed
Oct 30, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790409
HISTAMINE BINDING POLYPEPTIDES AND USES THEREOF
3y 10m to grant Granted Nov 10, 2026
Patent 12782350
MACHINE READABLE DIAGNOSTIC TEST DEVICES AND METHODS AND APPARATUS TO MAKE AND/OR PROCESS THE SAME
3y 11m to grant Granted Nov 03, 2026
Patent 12768839
ANALYTE DETECTION USING ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY-BASED IMAGINARY IMPEDANCE MEASUREMENT
3y 10m to grant Granted Oct 20, 2026
Patent 12663424
ANTIBODY SPECIFICALLY BINDING TO WRS PROTEIN, AND USE THEREOF
4y 5m to grant Granted Jun 23, 2026
Patent 12656345
METHOD FOR DIAGNOSING HUMAN T-CELL LEUKEMIA VIRUS TYPE 1 (HTLV-1)-RELATED DISEASE
4y 1m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
64%
Grant Probability
99%
With Interview (+54.1%)
3y 11m (~6m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 76 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month